Abstract
Simple SummaryAccurate primary staging for determining the extent of prostate cancer is crucial for planning treatment in high-risk patients for distant metastases. Recurrence is still common after curative intent therapy, in spite of developments in the clinical nomograms for appropriate pre-treatment screening of patients for selective therapeutic approaches. This is partly due to suboptimal diagnostic performance of standard conventional imaging modalities such as computed tomography and bone scintigraphy. Molecular imaging by means of PET/CT and PET/MRI imaging using novel specific radiotracers might provide more precise staging of disease, allowing for better personalized treatments. This article reviews current developments and future trends for functional hybrid PET-targeted imaging in primary staging of prostate cancer.Accurate primary staging is the cornerstone in all malignancies. Different morphological imaging modalities are employed in the evaluation of prostate cancer (PCa). Regardless of all developments in imaging, invasive histopathologic evaluation is still the standard method for the detection and staging of the primary PCa. Magnetic resonance imaging (MRI) and computed tomography (CT) play crucial roles; however, functional imaging provides additional valuable information, and it is gaining ever-growing acceptance in the management of PCa. Targeted imaging with different radiotracers has remarkably evolved in the past two decades. [111In]In-capromab pendetide scintigraphy was a new approach in the management of PCa. Afterwards, positron emission tomography (PET) tracers such as [11C/18F]choline and [11C]acetate were developed. Nevertheless, none found a role in the primary staging. By introduction of the highly sensitive small molecule prostate-specific membrane antigen (PSMA) PET/CT, as well as recent developments in MRI and hybrid PET/MRI systems, non-invasive staging of PCa is being contemplated. Several studies investigated the role of these sophisticated modalities in the primary staging of PCa, showing promising results. Here, we recapitulate the role of targeted functional imaging. We briefly mention the most popular radiotracers, their diagnostic accuracy in the primary staging of PCa, and impact on patient management.
Highlights
Prostate cancer (PCa) is the second most commonly diagnosed cancer and the fifth leading cause of cancer-related death in men [1]
Molecular imaging using nuclear medicine modalities plays a crucial role in the management of prostate cancer (PCa)
Whole-body positron emission tomography (PET)/Magnetic resonance imaging (MRI) apparently performs similar to PET/computed tomography (CT) in the detection of distant metastasis
Summary
Prostate cancer (PCa) is the second most commonly diagnosed cancer and the fifth leading cause of cancer-related death in men [1]. Similar to [11C/18F]choline, [11C]acetate has non-specific uptake in the prostate gland It misses a fraction of tumoral foci, limiting its value in the detection of primary PCa. Again, the accuracy for the detection of LN metastasis is suboptimal. Büdaus et al were the first to evaluated the accuracy of [68Ga]Ga-PSMA PET/CT for the detection of metastatic LNs before radical prostatectomy [92] While both patient- and node-based sensitivity were low (33.3% and 27.3%, respectively), the specificity was excellent (100%). [68Ga]Ga-PSMA PET/CT detects primary PCa and provides accurate T-staging in approximately two-thirds of patients It is not an ideal imaging method for the evaluation of primary prostatic lesions. Regarding LN staging, 18F-labeled PSMA PET/CT shows variable sensitivity, depending on the node- or patient-based analyses The non-specific uptake in bone lesions, with benign nature, must be considered with caution to avoid misinterpretation
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have